Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) EBT (2020 - 2026)

Barinthus Biotherapeutics (BRNS) has disclosed EBT for 7 consecutive years, with -$5.6 million as the latest value for Q1 2026.

  • For Q1 2026, EBT rose 71.8% year-over-year to -$5.6 million; the TTM value through Mar 2026 reached -$52.5 million, up 19.66%, while the annual FY2025 figure was -$66.6 million, 8.83% down from the prior year.
  • EBT hit -$5.6 million in Q1 2026 for Barinthus Biotherapeutics, up from -$11.2 million in the prior quarter.
  • Across five years, EBT topped out at $14.8 million in Q2 2022 and bottomed at -$25.0 million in Q2 2023.
  • Average EBT over 5 years is -$12.3 million, with a median of -$15.6 million recorded in 2024.
  • Year-over-year, EBT soared 236.33% in 2022 and then tumbled 1195.21% in 2023.
  • Barinthus Biotherapeutics' EBT stood at -$23.2 million in 2022, then grew by 21.88% to -$18.1 million in 2023, then dropped by 13.68% to -$20.6 million in 2024, then soared by 45.79% to -$11.2 million in 2025, then surged by 50.27% to -$5.6 million in 2026.
  • According to Business Quant data, EBT over the past three periods came in at -$5.6 million, -$11.2 million, and -$14.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.